EyePoint Pharmaceuticals Inc. (EYPT)
Here's Why You Should Add EYPT Stock to Your Portfolio Now
EyePoint's Duravyu faces a key LUCIA study data readout in late 2026, with results potentially paving the way for an NDA filing in 2027.
EyePoint, Inc. (EYPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
EyePoint, Inc. (EYPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown
Eyepoint Pharmaceuticals (EYPT) plunged ~70% after its LUGANO Phase 3 trial for Duravyu in wet AMD failed the primary endpoint due to an anomalous cohort. EYPT's management argues the failure was driven by nine patients (4%) with vision loss unrelated to wet AMD, and highlights strong secondary endpoints and durability advantages. Upcoming LUCIA Phase 3 data in Q4 2026 is pivotal; a positive result could revive the Duravyu program and restore investor confidence.
EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
EyePoint's Duravyu misses the phase III wet AMD study's primary goal, sending shares down 67%, but shows lower treatment burden and durable disease control.
EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates
EyePoint (EYPT) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $0.85 per share a year ago.
Earnings Preview: EyePoint (EYPT) Q2 Earnings Expected to Decline
EyePoint (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears
Eyepoint Pharmaceuticals NASDAQ: EYPT executives said the company remains on track to report top-line data from its Phase 3 wet age-related macular degeneration program for DURAVYU, also known as EYP-1901, beginning in August, with a second pivotal trial expected to follow about two months later.
EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript
EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript
EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates
EyePoint (EYPT) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to a loss of $0.65 per share a year ago.
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment
Parkman bought 1,088,033 shares of EyePoint in the fourth quarter, marking a new stake for the fund. The quarter-end value of the EyePoint position increased by $19.88 million as a result.
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of “Buy” by Analysts
Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT - Get Free Report) has been assigned an average recommendation of "Buy" from the eight ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have given a buy rating and two have issued a strong buy rating on the
